By the time enrollment is getting up to speed, patients are going to want to be on such and not willing to enroll in CTIC's trial. With enrollment drying up, they just call an early halt (possibly timed after seeing data).
You couldn't possibly be suggesting that some biotechs actually try to run trials that will dragggggg oooouuuuutttt without actually inconveniently failing or succeeding?